Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy

被引：13

作者：

Banach, Monika ^{[1
,2
]}

Borowicz, Kinga K. ^{[2
]}

Czuczwar, Stanislaw J. ^{[1
,3
]}

机构：

[1] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland

[2] Med Univ Lublin, Dept Pathophysiol, Independent Unit Expt Neuropathophysiol, PL-20090 Lublin, Poland

[3] Inst Rural Hlth, Dept Physiopathol, PL-20092 Lublin, Poland

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 04期

关键词：

epilepsy; eslicarbazepine; eslicarbazepine acetate; partial seizures; PARTIAL-ONSET SEIZURES; STEADY-STATE PHARMACOKINETICS; MAXIMAL ELECTROSHOCK TEST; GATED SODIUM-CHANNELS; OPEN-LABEL EXTENSION; ACETATE BIA 2-093; LONG-TERM SAFETY; ANTIEPILEPTIC DRUGS; ISOBOLOGRAPHIC ANALYSIS; HEALTHY-SUBJECTS;

D O I：

10.1517/17425255.2015.1021686

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Introduction: Eslicarbazepine acetate (ESL) is a novel antiepileptic drug registered as the adjunctive treatment of partial-onset seizures in adults. As a third-generation medication, ESL is believed to have favorable efficacy/safety profile and pharmacokinetic properties in comparison with related drugs (carbamazepine and oxcarbazepine). Areas covered: The aim of the paper was to evaluate pharmacodynamic and pharmacokinetic properties of ESL with aspect to epilepsy treatment. The review of the scientific literature was based on the PubMed database, Clinical Trials, FDA and European Medicines Agency websites to elicit current information on drug metabolism, mechanism of action and efficacy/safety profile. Expert opinion: Results of clinical trials indicate that ESL possessed a favorable profile of anticonvulsant efficacy and tolerability as an add-on therapy in adult patients at daily doses of 800 and 1200 mg. Pediatric trials are in progress and their results will allow to characterize a role of ESL in the treatment of epilepsy in children.

引用

页码：639 / 648

页数：10

共 64 条

[1] Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects [J].

Almeida, L ;

Falcao, A ;

Maia, J ;

Mazur, D ;

Gellert, M ;

Soares-da-Silva, P .

JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) :1062-1066

[2] Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects [J].

Almeida, L. ;

Nunes, T. ;

Sicard, E. ;

Rocha, J. -F. ;

Falcao, A. ;

Brunet, J. -S. ;

Lefebvre, M. ;

Soares-da-Silva, P. .

ACTA NEUROLOGICA SCANDINAVICA, 2010, 121 (04) :257-264

[3] Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy [J].

Almeida, Luis ;

Minciu, Ioana ;

Nunes, Teresa ;

Butoianu, Nicolina ;

Falcao, Amilcar ;

Magureanu, Sandra-Adriana ;

Soares-da-Silva, Patricio .

JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (08) :966-977

[4] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment [J].

Almeida, Luis ;

Potgieter, J. Hendrick ;

Maia, Joana ;

Potgieter, M. Alida ;

Mota, Fernando ;

Soares-da-Silva, P. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) :267-273

[5] Eslicarbazepine acetate (BIA 2-093) [J].

Almeida, Luis ;

Soares-da-Silva, Patricio .

NEUROTHERAPEUTICS, 2007, 4 (01) :88-96

[6] Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels [J].

Ambósio, AF ;

Silva, AP ;

Malva, JO ;

Soares-da-Silva, P ;

Carvalho, AP ;

Carvalho, CM .

BIOCHEMICAL PHARMACOLOGY, 2001, 61 (10) :1271-1275

[7] Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons:: A comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093 [J].

Araújo, IM ;

Ambrósio, AF ;

Leal, EC ;

Verdasca, MJ ;

Malva, JO ;

Soares-Da-Silva, P ;

Carvalho, AP ;

Carvalho, CM .

EPILEPSIA, 2004, 45 (12) :1498-1505

[8] Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy [J].

Ben-Menachem, E. ;

Gabbai, A. A. ;

Hufnagel, A. ;

Maia, J. ;

Almeida, L. ;

Soares-da-Silva, P. .

EPILEPSY RESEARCH, 2010, 89 (2-3) :278-285

[9] Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives [J].

Benes, J ;

Parada, A ;

Figueiredo, AA ;

Alves, PC ;

Freitas, AP ;

Learmonth, DA ;

Cunha, RA ;

Garrett, J ;

Soares-da-Silva, P .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (14) :2582-2587

[10] Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) [J].

Bialer, M ;

Johannessen, SI ;

Kupferberg, HJ ;

Levy, RH ;

Perucca, E ;

Tomson, T .

EPILEPSY RESEARCH, 2004, 61 (1-3) :1-48

← 1 2 3 4 5 6 7 →